Cargando…
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
Prostate cancer is a leading cause of cancer death in men. Despite recent advances in our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulate...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104084/ https://www.ncbi.nlm.nih.gov/pubmed/24875818 http://dx.doi.org/10.4103/1008-682X.127822 |